-
Mashup Score: 0Disseminated blastic plasmacytoid dendritic cell neoplasm - 1 year(s) ago
Sanam Loghavi, Joseph D. Khoury; Disseminated blastic plasmacytoid dendritic cell neoplasm, Blood, Volume 126, Issue 4, 23 July 2015, Pages 558, https://doi.org
Source: American Society of HematologyCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1
Myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) are reported in up to 20% patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), where a shared clonal origin is shown in individual case studies. In this study, we performed targeted next generating sequencing on multiple bone marrow (BM), skin or sorted cells from 51 BPDCN patients (68.7 years,14.4–84.7), and…
Source: NatureCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 2Grade I, II and III Follicular Lymphomas Express Ig VH Genes with Different Patterns of Somatic Mutation - Pathology & Oncology Research - 1 year(s) ago
Follicular lymphoma (FL) is an indolent, B-cell, non-Hodgkin’s lymphoma with varying cytological appearance and clinical behavior. The genetic hallmark of FL is the t(14;18) translocation, and as a germinal center derived entity it is also characterized by somatic hypermutation of the immunoglobulin heavy chain (IgH) gene. In an attempt to correlate this molecular signature with the cytological…
Source: SpringerLinkCategories: Hem/Oncs, Latest HeadlinesTweet-
But.. b/c I’m a sucker for #hemepath history.. let me remind you the criteria for grading FL in WHO 2016 And show you what we mean when we refer to centrocytes (small cleaved cells) vs. centroblasts (large transformed cells +nucleoli) image from https://t.co/xjHP7lw477 #WHOHEME https://t.co/CyJSPQPgnr
-
-
Mashup Score: 2
Abstract. Follicular lymphoma (FL) is a morphologically and genetically well-characterized B-cell non-Hodgkin lymphoma that can show predominantly follicular, c
Source: American Society of HematologyCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 6The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia - Leukemia - 2 year(s) ago
Prognostic scores support clinicians in selecting risk-adjusted treatments and in comparatively assessing different results. For patients with chronic-phase chronic myeloid leukemia (CML), four baseline prognostic scores are commonly used. Our aim was to compare the prognostic performance of the scores and to arrive at an evidence-based score recommendation. In 2949 patients not involved in any…
Source: NatureCategories: Latest Headlines, PathologyTweet
-
Mashup Score: 3The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia - Leukemia - 2 year(s) ago
Prognostic scores support clinicians in selecting risk-adjusted treatments and in comparatively assessing different results. For patients with chronic-phase chronic myeloid leukemia (CML), four baseline prognostic scores are commonly used. Our aim was to compare the prognostic performance of the scores and to arrive at an evidence-based score recommendation. In 2949 patients not involved in any…
Source: NatureCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Dendritic cell sarcoma: A pooled analysis including 462 cases with presentation of our case series - 2 year(s) ago
Dendritic cell tumors are extremely rare and current knowledge on these tumors is limited. The characteristics of three dendritic cell sarcoma subtype…
Source: www.sciencedirect.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Fig. 10 | Nature Communications - 2 year(s) ago
Proposed model of T-PLL development. Top: Projections from an ‘unaffected’ thymic emigrant (left) compared to the scenario of a post-thymic T-PLL precursor (right box) with inappropriate expression of TCL1 and deficient ATM. Effects of this postulated initiating core lesion of TCL1up/ATMdef on the key signaling branches and functions of ATM are highlighted by differential arrows. It includes…
Source: www.nature.comCategories: Hem/Oncs, Latest HeadlinesTweet-
So why is TCL1 overexpressed in T-PLL? b/c inv(14)(q11q32) & t(14;14)(q11;q32) juxtapose TCL1A to TCR enhancer loci. Aberrant ⬆️TCL1 >> enhanced AKT signaling & increased cell proliferation & survival. Additional mutations cooperate. #WHOHEME https://t.co/yjlKkek4y8 @NatureComms https://t.co/FhVsxXsost
-
-
Mashup Score: 0Alemtuzumab (Lemtrada) - Cambridge Neuroimmunology - 2 year(s) ago
The history of alemtuzumab use in multiple sclerosis The University of Cambridge has made a video on the history of alemtuzumab and published an article covering similar ground here. The beginnings of Alemtuzumab Campath-1H (now called alemtuzumab) was originally synthesized by Herman Waldmann at the Department of Pathology in Cambridge University (hence Cam-Path). Campath was licensed […]
Source: Cambridge NeuroimmunologyCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia - 2 year(s) ago
Abstract. In a Special Report, the T-PLL International Study group presents consensus criteria for the diagnosis, staging, and treatment response assessment of
Source: American Society of HematologyCategories: Hem/Oncs, Latest HeadlinesTweet-
For asymptomatic and indolent phase the recommendation is to observe (@aarongoodman33 recommends monthly CBC, see in clinic q3 month) these pts until signs of progression (See Table from @BloodJournal #WHOHEME https://t.co/QTgwMH9tjs https://t.co/LI4GiJwqbU
-
Bone marrow involvement can be interstitial, nodular and leukemic or a-leukemic. This was an example of a leukemic case @JoeKhouryMD and I published in @BloodJournal #bloodwork https://t.co/Wm5sOb9j5D @ASH_hematology #ASHimagebank #WHOHEME #hemepath #bpdcn #BPDCNDay 3/ https://t.co/KGIlACzcci